Braveheart Bio, Inc. (BRVE)
| Market Cap | 1.76B |
| Revenue (ttm) | n/a |
| Net Income | -80.23M |
| EPS | -2.63 |
| Shares Out | 64.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 162,456 |
| Open | 27.98 |
| Previous Close | 27.86 |
| Day's Range | 27.38 - 29.24 |
| 52-Week Range | 24.61 - 32.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About BRVE
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Financial Performance
Financial StatementsNews
Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart Bio opens at $30.20, IPO priced at $18 per share
Braveheart Bio (BRVE) – a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy and other serious cardiovascular diseases – priced 21.25M sha...
Braveheart Bio indicated to open at $30, IPO priced at $18
Braveheart Bio (BRVE) priced 21.25M shares at $18.00. The deal size was increased to 21.25M shares of common stock from 18.75M shares and priced above the $15.00-$17.00 range. Goldman Sachs,…
Braveheart Bio 21.25M share IPO priced at $18.00
The deal size was increased to 21.25M shares of common stock from 18.75M shares of common stock and priced above the $15.00-$17.00 range. Goldman Sachs, Jefferies, TD Cowen, Stifel and…
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy...
Braveheart, Attovia join next wave of biotech IPOs
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPO
Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Braveheart Bio IPO Registration Document (S-1)
Braveheart Bio has filed to go public with an IPO on the NASDAQ
Braveheart Bio Slides: FY 2026
Braveheart Bio has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 11, 2026.
Braveheart Bio Slides: American College of Cardiology 75th Annual Scientific Session presentation
Braveheart Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 28, 2026.